Nucleix's Lung EpiCheck detects lung cancer with 91% specificity, 74% sensitivity

Nucleix Ltd. (Rehovot, Israel) said its Lung EpiCheck blood test showed 91% specificity and 74% sensitivity for the early detection of lung cancer in a cohort of 181 lung cancer patients and 141 current or former smoker controls from 20 centers and three biobanks in Europe and Israel. Data will be presented at the World Conference on Lung Cancer in Toronto this month.

In 162 non-small cell lung cancer (NSCLC) samples, Lung EpiCheck correctly identified about 70% of patients, including 59% of stage I patients, 77% of stage II patients, 76% of stage III patients and 83% of stage IV patients. In 13 small cell lung cancer (SCLC) patients, Lung EpiCheck correctly identified 92% of patients...